Higher patient cost-sharing is associated with a lower likelihood of treatment augmentation in patients with depression who are treated with antidepressants.
Zhun Cao, PhD
Advertisement
Articles by Zhun Cao, PhD
Prior authorization for pregabalin in commercial insurance plans accomplished the objective of lower pregabalin utilization; however, there was no significant decrease in disease-related healthcare costs.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on AJMC
1
Flatiron’s AI-Driven Telescope Makes Data Access More User-Friendly
2
First Generic of Priftin Approved by FDA for Tuberculosis Treatment and Prevention
3
Mixed Phase 3 Results for IB6-Targeting ADC Raise Questions on Optimal Use in NSCLC
4
Social Factors May Match, Outpace Genetic Risk in Disease Prediction
5